The shares of
Mankind Pharma rockets on Thursday closed at Rs 1,913.75 up by 10 per cent after it
announced strong first quarter earnings on Wednesday with a favourable view by
Mankind net profit
Pharma reported a 66 per cent increase in consolidated net profit to Rs 494
crore in the June quarter. The company had reported a net profit of Rs 298
crore in the corresponding quarter of 2022-23.
company’s total income increased to Rs 2,637 crore in first quarter of the
current fiscal from Rs 2,196 crore in the year-ago period, Mankind Pharma said
in a regulatory filing.
Business achieved a robust 14% YoY growth in Q1FY24, while the Secondary Sales
demonstrated an impressive growth rate of 12.5%, showcasing a remarkable
outperformance of 1.5 times compared to the 8.5% growth in the Industry Primary
the other hand, the Consumer Healthcare segment witnessed a growth of 8% YoY
and 36% QoQ, Secondary sales in Prega News, HealthOKTM, Manforce condoms up by
30% YoY, 23% YoY and 11% YoY respectively in Q1FY24.
business witnessed a growth of 214% YoY in Q1FY24 aided by certain one-off
opportunities in the US.
company said its board has approved the re-appointment of Ramesh Juneja as its
chairman and Rajeev Juneja as vice-chairman and managing director.